TAZ antibody (AA 201-292) (Cy7)
Quick Overview for TAZ antibody (AA 201-292) (Cy7) (ABIN1707470)
Target
See all TAZ AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 201-292
-
Predicted Reactivity
- Human,Mouse,Rat,Dog,Cow,Sheep
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Tafazzin
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- TAZ (Tafazzin (TAZ))
-
Alternative Name
- Tafazzin
-
Background
-
Synonyms: Barth syndrome, Cardiomyopathy dilated 3A X linked, EFE2, Endocardial fibroelastosis 2, Protein G4.5, Tafazzin, TAZ, TAZ protein, TAZ protein, TAZ_HUMAN.
Background: This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced, the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known.
-
Gene ID
- 6901
Target
-